Table 3.
Overview of the cross reactivity of every SARS-CoV-2 antibody assay for the total specificity cohort.
| Sample group |
micro-organism or diagnosis |
number of samples tested |
EI-S |
EI-N |
Id-N |
TD-S |
R-N |
DS-S |
TD-SN |
TF-S |
LFA PR-SN |
LFA TD-S |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG | IgM | IgG + IgM | IgG | IgM | IgG + IgM | |||||||||||
| Non-coronavirus Respiratory infection (n = 35) | adenovirus | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| bocavirus | 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Chlamydophila pneumoniae | 2 | – | – | – | 1 | – | – | – | – | – | 1 | 1 | – | 1 | 1 | |
| enterovirus | 3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| human metapneumovirus | 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| influenza A virus | 7 | 1 | – | – | – | – | 1 | 1 | – | – | – | – | – | 1 | 1 | |
| influenza B virus | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Legionella pneumophilae | 1 | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | |
| Mycoplasma pneumoniae | 3 | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| parainfluenza virus 1 | 3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| parainfluenza virus 2 | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| parainfluenza virus 3 | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| parainfluenza virus 4 | 1 | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | 1 | |
| rhinovirus | 4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| respiratory syncitial virus | 3 | 2 | 1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| Other human coronavirus infections (n = 19) | human coronavirus 229E | 4 | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 |
| human coronavirus HKU | 6 | – | 1 | – | – | – | – | – | – | – | – | – | – | 1 | 1 | |
| human coronavirus NL63 | 5 | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | |
| human coronavirus OC43 | 4 | – | 1 | – | – | – | 1 | 1 | – | – | – | – | 1 | 1 | 1 | |
| Systemic rheumatic disease (n = 10) | mixed connective tissue disease | 2 | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 |
| rheumatoid arthritis | 3 | – | – | 1 | – | – | – | – | – | – | – | – | 1 | 2 | 2 | |
| systemic lupus erythematosus | 3 | – | – | – | – | – | – | – | – | – | – | – | 1 | 2 | 2 | |
| sjögren syndrome | 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Other pathogens (n = 21) | Borrelia burgdorferi (IgG) | 1 | – | 1 | – | – | – | – | – | – | – | – | – | – | – | – |
| cytomegalovirus | 3 | – | – | – | – | – | – | – | – | 1 | – | 1 | – | – | – | |
| epstein-barr virus | 3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| hepatitis A virus | 1 | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | 1 | |
| hepatitis B virus (HBsAg) | 2 | – | 1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| hepatitis C virus | 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| hepatitis E virus | 3 | – | – | – | – | – | – | 1 | – | 1 | – | 1 | – | – | – | |
| parvovirus | 2 | – | – | – | – | – | 1 | – | – | – | – | – | – | – | – | |
| Toxoplasma gondii | 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Treponema pallidum | 2 | – | 1 | – | – | – | 1 | – | – | 1 | – | 1 | – | 1 | 1 | |
| Total | 85 | 4 | 6 | 1 | 1 | 0 | 4 | 3 | 0 | 3 | 1 | 4 | 5 | 15 | 15 | |
Abbreviations: DS-S, Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin S.P.A., Italy); EI-N (Anti-SARS-CoV-2-NCP (Euroimmun, Germany); EI-S, Anti-SARS-CoV-2 (Euroimmun, Germany); Id-N, ID screen SARS-CoV-2-N (Id-vet, France); LFA PR-SN, COVID-PRESTO® (AAZ-LMB, France); LFA TD-S = TDR Covid-19 IgG + IgM Thera (Theradiag, France); R-N, Elecsys Anti-SARS-CoV-2 (Roche, Germany); TD-S, COVID-19 THERA02 (Theradiag, France); TD-SN, COVID19-LISA IgG (Theradiag, France); TF-S, EliA SARS-CoV-2 Sp1 IgG (Thermo Fisher Scientific, Sweden).